UroGen Pharma (NASDAQ: URGN) insider transactions
In the twelve months to 10 November 2026, executives and directors of UroGen Pharma reported 15 open-market sales of 125,343 shares ($4.8m) and 0 open-market purchases, by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 8 October 2026 | Degnan Chris | Chief Financial Officer | Option exercise | +4,483 | — | 6,763 | Form 4 |
| 8 October 2026 | Degnan Chris | Chief Financial Officer | Open-market sale | −2,202 | $36.69 | 4,561 | Form 4 |
| 8 September 2026 | Smith Jason Drew | General Counsel | Open-market sale | −1,519 | $42.54 | 53,141 | Form 4 |
| 8 September 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale | −871 | $42.92 | 59,882 | Form 4 |
| 7 September 2026 | Smith Jason Drew | General Counsel | Option exercise | +3,334 | — | 54,660 | Form 4 |
| 7 September 2026 | Schoenberg Mark | Chief Medical Officer | Option exercise | +1,667 | — | 60,753 | Form 4 |
| 26 August 2026 | Robinson James A. Jr. | Director | Option exercise | +2,000 | — | 8,000 | Form 4 |
| 20 August 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale | −60,677 | $47.05 | 59,086 | Form 4 |
| 9 July 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale, 10b5-1 plan | −10,000 | $40.00 | 119,763 | Form 4 |
| 22 June 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale, 10b5-1 plan | −10,000 | $35.01 | 129,763 | Form 4 |
| 8 June 2026 | Schoenberg Mark | Chief Medical Officer | Option exercise | +10,000 | — | 144,985 | Form 4 |
| 8 June 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale | −5,222 | $27.30 | 139,763 | Form 4 |
| 26 May 2026 | Robinson James A. Jr. | Director | Option exercise | +2,000 | — | 6,000 | Form 4 |
| 8 May 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale, 10b5-1 plan | −10,000 | $30.00 | 134,985 | Form 4 |
| 3 February 2026 | Smith Jason Drew | General Counsel | Open-market sale | −2,654 | $19.69 | 52,934 | Form 4 |
| 3 February 2026 | Smith Jason Drew | General Counsel | Open-market sale | −1,608 | $19.69 | 51,326 | Form 4 |
| 3 February 2026 | Smith Jason Drew | General Counsel | Open-market sale | −3,217 | $19.69 | 55,588 | Form 4 |
| 3 February 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale | −1,844 | $19.69 | 150,514 | Form 4 |
| 3 February 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale | −1,843 | $19.69 | 148,671 | Form 4 |
| 3 February 2026 | Schoenberg Mark | Chief Medical Officer | Open-market sale | −3,686 | $19.69 | 144,985 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the UroGen Pharma page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.